The CD95L inhibitor asunercept has shown a positive safety profile and promising efficacy in the phase I clinical trial in heavily transfusion-dependent patients diagnosed with lower risk MDS [12]. The gene discussed is FASLG; the disease is myelodysplastic syndrome.